Indications
Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
Composition
- Active substance
- ciclosporin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Verkazia
- Active substance
- ciclosporin
- ATC code
- S01XA18
- Group
- Sensory organs
- Therapeutic area
- Conjunctivitis, Keratitis
- Marketing authorisation holder
- Santen Oy
- Status
- Authorised
- EU authorisation
- 6 Jul 2018
- EMA product number
- EMEA/H/C/004411